RxDoctor Payments Data

Victoria Hogg

Psychiatric/Mental Health · Alexandria, LANPI 1134723307

Payments from drug & device makers

$2,612in general payments, 2019–2025

Across 134 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$758
  • AbbVie$609
  • Otsuka America Pharmaceutical, Inc.$445
  • Neurocrine Biosciences, Inc.$209
  • Vanda Pharmaceuticals Inc.$142
  • Corium, LLC$112
  • plus $338 from 8 others

What the payments were for

  • Food & beverage$2,612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,612 in reported general payments places this provider in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$4,176
Medicare patients
29
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl24$40,050
RexultiBrexpiprazole13$20,868
Quetiapine Fumarate70$753
Oxcarbazepine38$716
Guanfacine Hcl23$638
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$598
Duloxetine Hcl44$428
Prazosin Hcl37$364
Doxepin Hcl17$346
Divalproex Sodium ErDivalproex Sodium18$293
Clonazepam48$266
Buspirone Hcl25$253
Fluoxetine Hcl60$186
Lithium Carbonate11$184
Lamotrigine25$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$609$40,05024 claims
Otsuka America Pharmaceutical, Inc.Rexulti$445$20,86813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →